significantly between twin pregnancies who received ACS and twin pregnancies who did not (29.1% vs. 26.6%, p¼0.55). The three groups did not differ in the lowest neonatal blood glucose levels measured in the first or second day of life (p¼0.08 and p¼0.12, respectively), or through the entire hospitalization (p¼0.06). Compared to singleton pregnancy, exposure to ACS in twin gestation was significantly associated with lower rate of neonatal hypoglycemia after adjustment for maternal age and BMI, gestational diabetes, GA at delivery, mode of delivery and birth weight (OR 0.67, p¼0.04). CONCLUSION: To the best of our knowledge, this is the first study to examine the association between ACS exposure in preterm twins and neonatal hypoglycemia. Our findings suggest ACS administration in preterm twins is not associated with neonatal hypoglycemia. This is in contrast to the finding of neonatal hypoglycemia in late preterm singletons, and may be due to higher volume of distribution and a shorter half-life of betamethasone in twin pregnancies compared to singleton pregnancies. OBJECTIVE: Patient engagement and motivation is critical in the management of gestational diabetes. We sought to determine if an iOs mobile application designed specifically for women with gestational diabetes (GDM) would change the need to start pharmacologic therapy. STUDY DESIGN: Prospective randomized IRB-sanctioned trial of women with GDM (Coustan criteria) conducted at a single tertiary center. GlucoseMama (GM) is an iOS application designed specifically for GDM to positively reinforce self-monitoring of blood sugar, give positive feedback using text messaging, and suggest healthy meal choices in the form of recipes and meal plans. Women were randomized to GM versus traditional logging (TL)(pen and paper). Inclusion criteria: Women diagnosed with GDM at 24-34 weeks with singleton gestations. Primary outcome was need to start pharmacologic therapy (metformin, glyburide and/or insulin) at any point during pregnancy. Secondary outcomes: compliance with weekly log review, number of blood sugars logged, and delivery, neonatal, and postpartum outcomes. Power analysis revealed a sample size of 12 patients in each arm to reach statistical significance. P< 0.05 was considered significant. RESULTS: A total of 23 women were randomized. No differences were seen in need for pharmacologic therapy between GlucoseMama (69.2%) and traditional logging (60%) (p>0.05). Compliance with weekly log review was improved with GM (100% with GM, 70% with TL), but no difference was seen in the number of blood sugars logged each week (65.9% v. 61.1%). There were no differences in delivery or neonatal outcomes (including delivery mode, intrapartum complications, Apgar scores, cord pH and incidence of neonatal hypoglycemia). Postpartum, completion of the 2-hour glucose tolerance test (GTT), sustained breastfeeding, and initiation of birth control were higher in women who had used GM antenatally (Table 1) . CONCLUSION: While there were no differences in the incidence of pharmacologic therapy between groups, GlucoseMama improved reporting compliance during pregnancy and impacted multiple aspects of postpartum care.
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